Akari Therapeutics, Plc

Healthcare · Biotechnology · United States

Last price 8.24 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 18.83M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company’s lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is ...